Investor Relations

Our mission is simple—help patients across the globe who suffer from pain and chronic conditions. We are doing this by harnessing the power of nVNS, innovation, and technology to develop a safe and clinically backed treatment. Bringing new treatments to market will help improve patients' treatment options and lives.

electroCore, Inc. Announces Appointment of Ardelle Ferris as Vice President of Managed Care

October 30, 2018 at 8:00 AM EDT

BASKING RIDGE, N.J., Oct. 30, 2018 (GLOBE NEWSWIRE) -- electroCore, Inc. (“electroCore”) (Nasdaq:ECOR), a commercial-stage bioelectronic medicine company, today announced the appointment of Ardelle Ferris to a new position within the company, Vice President of Managed Care. Ardelle brings over 20 years of experience in national account management with PBMs and commercial health plans. She joins electroCore after her most recent role as the Head of National Accounts at Intarcia Therapeutics.

“Ardelle is a highly-anticipated, welcomed addition to our growing market access team, and her leadership will be critical to shaping our PBM and commercial payer relationship strategies,” said Frank Amato, Chief Executive Officer of electroCore, “Her specialized background and industry expertise in managed care combined with her collaborative spirit will be instrumental in growing reimbursement coverage for gammaCore Sapphire in the United States.”

In her new role, Ardelle will be tasked with recruiting, training and leading electroCore’s field Market Access team, accountable for achieving national sales goals set for several market segments, and contracting. Prior to her time with Intarcia Therapeutics, Ardelle held National and Senior Account Manager positions at Pfizer and Vertex Pharmaceuticals for over 15 years. She holds a Bachelor of Arts in Nursing degree from the University of Jamestown, and is a Registered Nurse.

About electroCore, Inc.
electroCore, Inc. is a commercial-stage bioelectronic medicine company dedicated to improving patient outcomes through its platform non-invasive vagus nerve stimulation therapy initially focused on the treatment of multiple conditions in neurology and rheumatology. The company’s initial targets are the acute treatment of migraine and episodic cluster headache.

For more information, visit  

Forward-Looking Statements
This press release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, but are not limited to, statements about electroCore's business prospects and product development plans, its pipeline or potential markets for its technologies, and other statements that are not historical in nature, particularly those that utilize terminology such as "anticipates," "will," "expects," "believes," "intends," other words of similar meaning, derivations of such words and the use of future dates. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the ability to raise the additional funding needed to continue to pursue electroCore’s business and product development plans, the inherent uncertainties associated with developing new products or technologies, the ability to commercialize gammaCore™, competition in the industry in which electroCore operates and overall market conditions. Any forward-looking statements are made as of the date of this press release, and electroCore assumes no obligation to update the forward-looking statements or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law.  Investors should consult all of the information set forth herein and should also refer to the risk factor disclosure set forth in the reports and other documents electroCore files with the SEC available at

Greg Chodaczek or Lynn Lewis
Gilmartin Group
(646) 924-1769
Alexandra Canale
GCI Health
(617) 921-9353